top of page
  • mmahomed2

QB3 Biotech Pitch Summit

Valitor was among a select group of early-stage start up companies that were invited to participate in the 2018 QB3 Biotech Pitch Summit. This was an exciting opportunity to share Valitor’s science and business plan to top-tier life science investors from around the world. This event was the kick-off of our Series A fundraising, and we were thrilled but the positive reception we received from potential investors.

44 views0 comments

Recent Posts

See All

Valitor is proud to announce the final close of our Series A financing, co-lead by the Berkeley Catalyst Fund and ShangPharma Innovations. This round oversubscribed our initial offering, and we raised

Valitor has been awarded a Phase I SBIR grant from the National Cancer Institute. This project will support validation of our platform technology to generate long-acting immunotherapies that can provi

bottom of page